The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

In September, ONL announced the closing of a $65 million Series D financing round, led by Johnson & Johnson Innovation – JJDC, Inc. The Series D funding supports the advancement of the development of ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

ArMaDa clinical trial is set to assess the safety and efficacy of unilateral subretinal administration of OCU410 in patients ...

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

Visakhapatnam: Women are 50% to 60% more susceptible to a range of eye disorders compared to men, according to doctors, many ...

Reticular pseudodrusen and subretinal hyperreflective material are among the OCT findings that may predict macular atrophy in ...

The ArMaDa clinical trial is currently being performed at 13 leading retinal surgery centers across the U.S. Dosing in the OCU410 ArMaDa clinical trial will be completed in early 2025 and the Company ...

Reducing the risk of eye diseases involves a combination of lifestyle changes, protective measures and regular eye care ...

Geographic atrophy, also known as GA, is a form of advanced dry macular degeneration where patients can develop vision loss from areas ... Up to 75% of people living with the condition in the United ...

Valiltramiprosate is under clinical development by Alzheon and currently in Phase II for Unspecified Central Nervous System Disorders.

It acts by targeting MDM2-p53. It is a small-molecule mouse double minute 2 homolog (MDM2) inhibitor. The drug candidate was also under development for the treatment of dry age related macular ...